文献速递生殖医学

不孕女性使用促生育药物后结直肠癌风险:一项丹麦大型人群队列研究结果

Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility.
PubMed 文献 · Fertil Steril · 2022-08-28

该研究基于丹麦不孕队列纳入1995-2017年20-45岁不孕女性148,036例,其中205例确诊结直肠癌,采用Cox比例风险模型分析促生育药物与结直肠癌的关联。曾使用克罗米芬与较低的结直肠癌发生率相关(调整HR 0.68,95%CI 0.50-0.93),但仅见于首次使用克罗米芬超过8年者;其他促生育药物未见明显关联。作者认为克罗米芬可能降低结直肠癌风险,但不能排除与基础疾病相关或为偶然发现,需进一步大型流行病学研究。

要点

  • 148,036例不孕女性中205例确诊结直肠癌,曾用克罗米芬者结直肠癌发生率较低(调整HR 0.68,95%CI 0.50-0.93)。
  • 该较低发生率仅见于首次使用克罗米芬超过8年者(调整HR 0.52,95%CI 0.36-0.75)。
  • 其他类型促生育药物与结直肠癌未见明显关联;促性腺激素与直肠癌风险降低仅有提示性关联(调整HR 0.46,95%CI 0.20-1.08)。

核心结论

  • 在不孕女性中,大多数类型促生育药物的使用与结直肠癌无关。
  • 克罗米芬可能降低结直肠癌风险,促性腺激素可能降低直肠癌风险,但不能排除这些发现更多与基础疾病相关或为偶然发现。
  • 作者认为该研究结果应进一步在大型流行病学研究中探讨。

研究设计与样本

  • 基于人群的队列研究,研究队列来自丹麦不孕队列,纳入1995-2017年居住在丹麦的所有20-45岁不孕女性。
  • 最终研究队列共148,036例女性,其中205例确诊结直肠癌。
  • 促生育药物使用信息、结直肠癌诊断、协变量及生命状态来自丹麦不孕队列和丹麦国家登记。
  • 采用Cox比例风险模型估计结直肠癌总体及直肠癌、结肠癌分别的风险比(HR)和95%置信区间(CI),并调整潜在混杂因素。

主要发现

  • 曾使用克罗米芬与较低的结直肠癌发生率相关:未调整HR 0.67(95%CI 0.51-0.89),调整HR 0.68(95%CI 0.50-0.93)。
  • 该较低发生率仅见于首次使用克罗米芬超过8年者:未调整HR 0.56(95%CI 0.41-0.76),调整HR 0.52(95%CI 0.36-0.75)。
  • 其他类型促生育药物的使用与结直肠癌之间未发现明显关联。
  • 结肠癌和直肠癌分别分析的结果相似,但促性腺激素使用与直肠癌风险降低仅有提示性关联:调整HR 0.46(95%CI 0.20-1.08)。

局限性

  • 作者指出不能排除这些发现可能更多与这些女性的基础疾病相关或为偶然发现。
  • 作者认为该研究结果应进一步在大型流行病学研究中探讨。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the association between use of fertility drugs and colorectal cancer among women with infertility. DESIGN: Population-based cohort study. SETTING: Not applicable. PATIENT(S): The study cohort was obtained from the Danish Infertility Cohort and consisted of all women with infertility aged 20-45 years living in Denmark during 1995-2017. INTERVENTION(S): Information on the use of specific types of fertility drugs, colorectal cancer diagnoses, covariates, and vital status were obtained from the Danish Infertility Cohort and Danish national registers. MAIN OUTCOME MEASURE(S): Cox proportional hazard models adjusted for potential confounders were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for colorectal cancer overall and rectal and colon cancer separately. RESULTS(S): Among 148,036 women in the final study cohort, 205 women were diagnosed with colorectal cancer. Ever use of clomiphene citrate (CC) was associated with a lower rate of colorectal cancer (unadjusted HR, 0.67; 95% CI, 0.51-0.89; adjusted HR, 0.68; 95% CI, 0.50-0.93). However, the lower rate was only seen among women who first used CC >8 years ago (unadjusted HR, 0.56; 95% CI, 0.41-0.76; adjusted HR, 0.52; 95% CI, 0.36-0.75). No marked associations were found between the use of any of other types of fertility drugs and colorectal cancer. The results for colon and rectal cancer analyzed separately were similar, except for a suggestion of a decreased risk of rectal cancer associated with the use of gonadotropins (adjusted HR, 0.46; 95% CI, 0.20-1.08). CONCLUSION(S): Among women with infertility, the use of most types of fertility drugs was not associated with colorectal cancer. However, CC may decrease the risk of colorectal cancer and gonadotropins might decrease the risk of rectal cancer, but we cannot rule out that these findings may be more related to the underlying conditions in these women or are chance findings. Consequently, the results from this study should be investigated further in large epidemiological studies.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Møller M, Kjær SK, Lindquist S, et al. Risk of colorectal cancer after use of fertility drugs-results from a large Danish population-based cohort of women with infertility. Fertil Steril. 2022. PMID: 36041966. doi:10.1016/j.fertnstert.2022.06.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。